ストックスクリーナーアプリを入手
7.13
0.56%
-0.04
アフターアワーズ：
7.13
前日終値:
$7.17
開ける：
$7.11
24時間の取引高:
341.73K
Relative Volume:
0.99
時価総額：
$277.62M
収益：
$5.74M
当期純損益:
$-166.12M
株価収益率:
-1.7835
EPS:
-3.9978
ネットキャッシュフロー:
$-131.64M
1週間 パフォーマンス:
+1.86%
1か月 パフォーマンス:
-1.52%
6か月 パフォーマンス:
-42.96%
1年 パフォーマンス:
+36.59%
1日の値動き範囲:
$7.00
$7.17
1週間の範囲:
$6.76
$7.4228
52週間の値動き範囲:
$5.02
$16.45
Entrada Therapeutics Inc Stock (TRDA) Company Profile
名前
Entrada Therapeutics Inc
セクター
電話
857-305-1825
住所
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
7.13 | 295.92M | 5.74M | -166.12M | -131.64M | -3.9978 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2026-02-11 | 開始されました | Guggenheim | Buy |
| 2026-01-28 | 開始されました | Oppenheimer | Outperform |
| 2024-12-06 | 開始されました | ROTH MKM | Buy |
| 2024-01-05 | 開始されました | Oppenheimer | Outperform |
| 2023-04-03 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Entrada Therapeutics Inc (TRDA) 最新ニュース
MPM BIOVENTURES 2018, L.P. Disposes 86,482 Shares of Entrada Therapeutics Between September 1-3, 2026 - Kalkine Media
Entrada Therapeutics' R&D President Sethuraman Natarajan Forfeits 2,079 Shares at $7.14 Each on September 2, 2026 - Kalkine Media
Entrada Therapeutics CFO Wentworth Kory James Forfeits 1,733 Shares at $7.14 Each (NASDAQ: TRDA) - Kalkine Media
TRDAEntrada Therapeutics Inc Revenue Breakdown - Finviz
Mpm Bioventures, 10% owner, sells $617k in Entrada Therapeutics By Investing.com - Investing.com Nigeria
Mpm Bioventures 2018 sells $617k Entrada Therapeutics shares By Investing.com - Investing.com Nigeria
Mpm Bioventures, 10% owner, sells $617k in Entrada Therapeutics - Investing.com
Institutional holder sells Entrada (NASDAQ: TRDA) shares over three days - Stock Titan
MPM funds sell Entrada (TRDA) shares without 10b5-1 plan - Stock Titan
Entrada Therapeutics (TRDA) CEO sale is tax-driven, still owns 517,290 shares - Stock Titan
Automatic tax sale trims Entrada Therapeutics (TRDA) CFO stake - Stock Titan
Automatic tax sale trims Entrada Therapeutics (TRDA) insider stake - Stock Titan
Automatic tax sale trims Entrada Therapeutics (TRDA) COO holdings - Stock Titan
Oppenheimer Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Liquidity Mapping Around (TRDA) Price Events - news.stocktradersdaily.com
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Mpm Bioventures 2018 sells $615,777 in Entrada Therapeutics stock By Investing.com - Investing.com Nigeria
Mpm Bioventures 2014 L.P. sells $615,777 of Entrada Therapeutics stock By Investing.com - Investing.com South Africa
Mpm Bioventures 2014 L.P. sells $615,777 of Entrada Therapeutics stock - Investing.com
Entrada Therapeutics (NASDAQ: TRDA) insider sells near $7 a share - Stock Titan
Entrada Therapeutics (TRDA) backer MPM funds sell 86,914 shares around $7 - Stock Titan
We Think Entrada Therapeutics (NASDAQ:TRDA) Needs To Drive Business Growth Carefully - Sahm
Mpm Bioventures 2018 sells $461,545 of Entrada Therapeutics stock By Investing.com - Investing.com Nigeria
Mpm Bioventures sells $461,545 in Entrada Therapeutics stock By Investing.com - Investing.com Australia
Entrada Therapeutics (TRDA) 10% owner sells shares outside a 10b5-1 plan - Stock Titan
Analysts Offer Insights on NA Companies: Rapport Therapeutics, Inc. (RAPP) and SpaceX (SPCX) - The Globe and Mail
Entrada (TRDA) Results Breakdown: Reported EPS Tops Expectations at the Close; Investor Response: Shares Move 2.31% Lower at the CloseShare Repurchase Impact - vinanet.vn
Entrada (TRDA) Earnings Update: Profit Per Share Surpasses Its Benchmark on the Day; Share Move: Shares Move Higher 7.02%Analyst Earnings Estimate - vinanet.vn
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Celcuity (CELC) and Parabilis Medicines, Inc. (PBLS) - The Globe and Mail
(TRDA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Entrada Therapeutics Inc (TRDA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
HC Wainwright Analysts Lower Earnings Estimates for TRDA - marketbeat.com
Roth MKM Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Raises Target Price to $11 - Moomoo
Entrada Therapeutics director Kush Parmar sells $1.08 million in shares By Investing.com - Investing.com India
Major Insider Moves Shake Up Entrada Therapeutics Inc. Stock - TipRanks
Entrada Therapeutics director Kush Parmar sells $1.08 million in shares - Investing.com India
5am Ventures V, L.P. sells $431,829 of Entrada Therapeutics stock By Investing.com - Investing.com South Africa
5am Ventures V, L.P. sells $431,829 of Entrada Therapeutics stock - Investing.com
5AM Ventures V reports Entrada Therapeutics share disposal worth $431,620 - Bitget
Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $358,371.45 in Stock - MarketBeat
Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Director Sells $358,371.45 in Stock - MarketBeat
Entrada Therapeutics (TRDA): 5AM Ventures-linked funds sell 62,811 shares, retain over 1.09M - Stock Titan
Entrada Therapeutics Inc (TRDA) Stock News Today - TradingKey
Analysts’ Top Healthcare Picks: Insulet (PODD), Entrada Therapeutics Inc (TRDA) - The Globe and Mail
Entrada Therapeutics (NASDAQ:TRDA) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Entrada Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Entrada Therapeutics Submits Q2 2026 10-Q Report to SEC - Kalkine Media
Entrada Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Entrada Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Entrada Therapeutics Inc (TRDA) 財務データ
収益
当期純利益
現金流量
EPS
Entrada Therapeutics Inc (TRDA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| MPM BioVentures 2014, L.P. | 10% Owner |
Aug 24 '26 |
Sale |
7.34 |
21,623 |
158,713 |
4,359,439 |
| MPM BioVentures 2014, L.P. | 10% Owner |
Aug 26 '26 |
Sale |
7.06 |
14,569 |
102,857 |
4,318,348 |
| MPM BIOVENTURES 2018, L.P. | 10% Owner |
Aug 25 '26 |
Sale |
7.54 |
26,522 |
199,976 |
4,332,917 |
| MPM BIOVENTURES 2018, L.P. | 10% Owner |
Aug 24 '26 |
Sale |
7.34 |
21,623 |
158,713 |
4,359,439 |
| MPM BIOVENTURES 2018, L.P. | 10% Owner |
Aug 26 '26 |
Sale |
7.06 |
14,569 |
102,857 |
4,318,348 |
| PARMAR KUSH | Director |
Aug 10 '26 |
Sale |
7.00 |
92,444 |
647,108 |
2,691,337 |
| PARMAR KUSH | Director |
Aug 07 '26 |
Sale |
6.85 |
52,317 |
358,371 |
2,783,781 |
| PARMAR KUSH | Director |
Aug 06 '26 |
Sale |
7.00 |
10,494 |
73,458 |
2,836,098 |
| 5AM Ventures V, L.P. | 10% Owner |
Aug 07 '26 |
Sale |
6.85 |
52,317 |
358,371 |
2,783,781 |
| 5AM Ventures V, L.P. | 10% Owner |
Aug 06 '26 |
Sale |
7.00 |
10,494 |
73,458 |
2,836,098 |
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):